| Identification | Back Directory | [Name]
A 887826 | [CAS]
1266212-81-0 | [Synonyms]
A 887826
5-(4-Butoxy-3-chlorophenyl)-N-[[2-(4-Morpholinyl)-3-pyridinyl]Methyl]-3-pyridinecarboxaMide
3-Pyridinecarboxamide, 5-(4-butoxy-3-chlorophenyl)-N-[[2-(4-morpholinyl)-3-pyridinyl]methyl]- | [Molecular Formula]
C26H29ClN4O3 | [MDL Number]
MFCD20926345 | [MOL File]
1266212-81-0.mol | [Molecular Weight]
480.99 |
| Chemical Properties | Back Directory | [Boiling point ]
711.5±60.0 °C(Predicted) | [density ]
1.230±0.06 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMSO: ≥5mg/mL | [form ]
powder | [pka]
8.85±0.46(Predicted) | [color ]
white to beige |
| Hazard Information | Back Directory | [Uses]
A structurally novel, potent and voltage-dependent Nav1.8 sodium channel blocker that attenuates neuropathic tactile allodynia in rats | [Biological Activity]
a 887826 is a potent and voltage-dependent nav1.8 sodium channel blocker. it blocked recombinant human nav1.8 channels with an ic50 value of 11nm [1].voltage-gated sodium channels are important in the generation and propagation of action potential. at least 9 genes encode functional sodium channels, namely nav1.1-nav1.9. nav1.8 is a ttx-resistant (ttx-r) sodium channel. nav1.8 is highly localized on primary sensory afferent neurons. nav1.8 is involved in the processing of nociceptive information.-100 mv without prepulse did make a resting state for rat drg neurons. prepulse to -40 mv did make an inactivated state for channels. in rat drg neurons in these two states, treatment with a 887826 at 1 μm significantly blocked ttxr na+ currents. a 887826 blocked ttx-r na+ currents with an ic50 value of 7.9 ± 0.2 nm (n= 5~9) when channels were in an inactivated state (-40 mv). a 887826 showed an ic50 value of 63.6 ± 0.2 nm (n=5~9) to less depolarized (at -60, -80 or -100 mv) ttx-r na+ currents. that meant a 887826 state-dependently blocked ttx-r na+ currents [1].knockdown of nav1.8 caused a significant reduction in mechanical hyperalgesia and allodynia in rat models of inflammatory and neuropathic pain. suppression of nav1.8 expression also reduced visceral pain in several experimental models. activation of nav1.8 sodium channels primarily drove nociceptor excitability under cold conditions. a rat spinal nerve ligation model of neuropathic pain was used. oral administration with a 887826 dose-dependently attenuated tactile allodynia in this pain model. the range of free plasma concentrations of a 887826 to produce analgesic efficacy in a spinal nerve ligation model was 3-10 nm. this was consistent with the ic50 value for blocking rat drg ttx-r sodium currents [1]. | [in vivo]
A-887826 (3-30 mg/kg; p.o.; 1 hour pre-treatment) significantly attenuates tactile allodynia in a rat neuropathic pain model[1].
| Animal Model: | Male Spraguee Dawley rats (200-300 g)[1] | | Dosage: | 3 mg/kg, 10 mg/kg, 30 mg/kg | | Administration: | Oral administration; 1 hour before testing; fourteen days after L5-L6 spinal nerve ligation | | Result: | Produced a dose-dependent attenuation of tactile allodynia in this experimental pain model. |
| [IC 50]
Nav1.8: 1.1 nM (IC50) | [storage]
Store at RT | [References]
[1]. zhang xf, shieh cc, chapman ml, et al. a-887826 is a structurally novel, potent and voltage-dependent nav1.8 sodium channel blocker that attenuates neuropathic tactile allodynia in rats. neuropharmacology, 2010, 59(3): 201-207. |
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
|